Drug Trial Radar · NCT05042401
A Trial of SHR-1703 in Asthma
Last checked: Nov 19, 2026Latest source record: Apr 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
23
Actual
Start
Oct 12, 2021
Primary completion
Jun 15, 2023
Study completion Jun 15, 2023
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SHR-1703 is a monoclonal antibody under development for severe asthma. This study is the first study in patients with asthma. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics ,pharmacodynamics and immunogenic characteristics of multiple subcutaneous injections of SHR-1703 in asthmatic patients.
Conditions
- Asthma
Interventions
SHR-1703Drug
SHR-1703 low dose
placeboDrug
placebo low dose
SHR-1703Drug
SHR-1703 high dose
placeboDrug
placebo high dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of adverse events of SHR-1703Time frame: From Day 1 to Day 281
- Severity of adverse events of SHR-1703Time frame: From Day 1 to Day 281
- Tolerability of adverse events of SHR-1703Time frame: From Day 1 to Day 281
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.